(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 February 2010 (25.02.2010)

PCT

(10) International Publication Number
WO 2010/020675 A1

(51) International Patent Classification:
C07D 487/04 (2006.01) *A61P 35/00* (2006.01)
A61K 31/519 (2006.01)

(21) International Application Number:
PCT/EP2009/060793

(22) International Filing Date:
20 August 2009 (20.08.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/091,037 22 August 2008 (22.08.2008) US


(71) Applicants *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH). **ASTEX THERAPEUTICS LTD.** [GB/GB]; 436 Cambridge Science Park, Milton Road, Cambridge CB4 0QA (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BESONG, Gilbert** [DE/GB]; Astex Therapeutics Ltd., 436 Cambridge Science Park, Milton Road, Cambridge CB4 0QA (GB). **BRAIN, Christopher Thomas** [GB/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **BROOKS, Clinton A.** [US/US]; 3274 Ridgecrest Rd., Smyrna, Georgia 30080 (US). **CONGREVE, Miles Stuart** [GB/GB]; 11A Orchard Road, Melbourn, Royston SG8 6HL (GB). **DAGOSTIN, Claudio** [IT/GB]; 1 Hillfield Road, Comberton CB23 7DB (GB). **HE, Guo** [US/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **HOU, Ying** [CN/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **HOWARD, Steven** [GB/GB]; Astex Therapeutics Ltd., 436 Cambridge Science Park, Milton Road, Cambridge CB4 0QA (GB). **LI, Yue** [CN/CN]; China Novartis Institutes for, BioMedical Research Co., Ltd., No. 8 Building, Lane 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong New Area Shanghai, 201203 (CN). **LU, Yipin** [CN/US]; Novartis Institutes for BioMedical Research, Inc., 400 Technology Square, Cambridge, Massachusetts 02139 (US). **MORTENSON, Paul** [GB/GB]; Astex Therapeutics Ltd., 436 Cambridge Science Park, Milton Road, Cambridge CB4 0QA (GB). **SMITH, Troy** [US/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **SUNG, Moo** [KR/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **WOODHEAD, Steven** [GB/GB]; Astex Therapeutics Ltd., 436 Cambridge Science Park, Milton Road,

[Continued on next page]

(54) Title: PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS



(57) Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.

WO 2010/020675 A1

Cambridge CB4 0QA (GB). **WRONA, Wojciech** [US/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US).

(74) **Agent**: **DYER, James**; Novartis Pharma Ag, Patent Department, CH-4002 Basel (CH).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*